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Abstract
Herpes zoster (shingles) is an infectious disease caused by the varicella-zoster virus. Following the active 
phase of chicken pox and the crusting of skin lesions the virus spreads to the spinal and cranial ganglia and 
the posterior horns of the spinal cord, where it can stay dormant for many years. In immunocompromised 
patients, especially cancer patients, the virus can undergo reactivation to produce herpes zoster. The average 
incidence of herpes zoster is 4 per 1000 cases and rapidly increases with age and the lifetime prevalence 
is estimated at 10–20%. The predominating symptom of the acute phase of the disease is burning pain 
accompanied by abnormal skin sensation. The skin lesions in the form of vesicles usually heal within 3–5 
weeks, unless a secondary bacterial infection ensues. After the skin lesions have healed, the pain may persist 
in some patients (9–14%) in the form of a chronic pain syndrome of various severity, usually unilaterally 
within one or several spinal dermatomes or the trigeminal nerve area. The first part of the paper discusses the 
pathomechanism, epidemiology, location, clinical manifestations and management of the acute phase of 
the disease. The second part provides a detailed discussion of the pathomechanism, risk factors, prevention 
and management of persistent postherpetic neuralgia according to evidence-based medicine, presenting 
the current state of knowledge on herpes zoster and postherpetic neuralgia. Over the years, the effective-
ness of treatment of persistent postherpetic neuralgia has been gradually improving, mainly as a result of 
the currently available medication (antidepressants + gabapentinoids + topical medication + opioids) and 
the increasing understanding of the pathomechanism of this condition.
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Introduction
Postherpetic neuralgia (PHN) is a classic example 
of neuropathic pain. Neuropathic pain is a type of 
non-nociceptive, chronic, severe and debilitating 
pain. Compared to patients with nociceptive pain, 
patients with neuropathic pain:
 — experience a greater severity of pain;
 — report a considerably lower quality of life;
 — use more analgesics;
 — report less symptomatic relief with treatment;
 — report a higher incidence of side effects;
 — fewer than 50% of the patients achieve satisfac-
tory, yet still partial symptomatic relief;
 — drugs proved to be effective in neuropathic pain 
are not used in the treatment;
 — the doses of drugs are usually too low to achieve 
a therapeutic effect;
 — despite using recommended drugs the pa-
tients continue to suffer from moderate pain 
[1–3].
The similarity between the pathomechanisms of 
neuropathic pain, depression and epilepsy has made 
it possible to use tricyclic antidepressants (e.g. am-
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itriptyline) or selective serotonin and noradrenaline 
reuptake inhibitors (venlafaxine, duloxetine) and, 
less frequently, selective serotonin reuptake inhibi-
tors (paroxetine, sertraline, citalopram) and antiepilep-
tic agents (gabapentin, pregabalin, carbamazepine, 
lamotrigine, valproic acid). In many cases, however, 
these drugs demonstrate poor effectiveness and there 
is an ongoing search for novel substances which 
might prove useful in the treatment of neuropathic 
pain. We take advantage of the effects exerted by 
muscle relaxants (baclofen), NMDA receptor antago-
nists (ketamine, dextromethorphan, magnesium), 
antiarrhythmics, which block pathological sodium 
channels (lidocaine IV, lidocaine patches 5% topi-
cally), bisphosphonates, alpha2-agonists (clonidine), 
cannabinoids, COX inhibitors, adenosine receptor 
agonists and glutamatergic receptor agonists. Sub-
stances acting via the TRPV1 vanilloid receptor (8% 
capsaicin) are the latest addition to this group [4, 5].
Herpes zoster
Pathomechanism
Herpes zoster is an infectious disease caused by 
the varicella-zoster virus (VZV) [6]. Once an episode 
of chickenpox in childhood has resolved and the 
skin lesions have healed, the virus travels to dor-
sal root ganglia (DRG), cranial nerve ganglia and 
the dorsal horns of the spinal cord, where it can 
remain inactive for many years. In certain clinical 
situations (e.g. cancer) the virus reactivates causing 
inflammation of the nerve called herpes zoster (or 
shingles). The mechanism of virus reactivation is un-
clear. Immunocompromised patients (patients with 
cancer, tuberculosis, HIV infection, patients treated 
with glucocorticosteroids or immunosuppressant 
drugs, patients with renal failure, patients with 
liver failure) and the elderly are known to be at an 
increased risk of virus reactivation. Reactivation of 
the virus results in its rapid proliferation in DRG, 
cranial nerve ganglia and dorsal horns of the spinal 
cord. In these areas inflammatory, haemorrhagic 
and necrotic lesions develop. In the nerves of one 
or several dermatomes affected, demyelination, fi-
brosis and cellular inflammatory reactions ensue. In 
the affected dermatomes, painful lesions in the form 
of fluid-filled vesicles develop. In the affected skin, 
ulcers and necrotic foci may develop [7–9]. Exami-
nations of skin sections collected in patients during 
the active phase of the disease show that a “se-
condary” viraemia is present in the skin, where the 
virus spreads from cell to cell. In the case of her-
pes zoster, the virus spreads via axonal transport, 
following reactivation in DRG, to keratinocytes and 
dermal cells. The diagnosis of herpes zoster is gener-
ally straight-forward due to the characteristic appear-
ance of the skin lesions that are localised unilaterally 
within one or several dermatomes and take the form 
of an erythematous rash with vesicles [7, 8].
Epidemiology
The incidence rate of herpes zoster averages be-
tween 3 and 4.5 per 1000 per year. The incidence 
increases with age, and this increase is particularly 
rapid in patients over the age of 60 years (6.8 per 
1000 per year) with the incidence rate exceeding 
10 per 1000 per year in patients over the age of 
80 years [9–11]. The VZV is an extremely conta-
gious pathogen belonging to the Herpesviridae 
family (herpeton in ancient Greek meant ‘reptile’). 
Its contagiousness is strictly associated with the 
cell, outside of which the virus virtually immediately 
loses its ability to infect [12, 13].
Location
The infection may affect sensory nerves of the 
trunk, extremities or cranial nerves. In more than 50% 
of the cases the disease affects intercostal nerves. Of 
the cranial nerves, the first division of the trigeminal 
nerve (herpes zoster ophthalmicus) is the most com-
monly affected (10–25% of the cases). The pain in 
herpes zoster localised in the head is generally more 
persistent and of longer duration [7–9].
Signs and symptoms
The onset of pain in herpes zoster usually pre-
cedes the appearance of skin lesions, although these 
two manifestations may develop concurrently. There 
are, however, reports of prodromal periods of pain 
of 100 and more days’ duration. Reactivation of the 
VZV may manifest as pain unaccompanied by skin 
lesions (zoster sine herpete), which makes the diagno-
sis difficult and delays treatment. Some patients, in 
addition to pain, complain of such symptoms as paraes-
thesia in the affected dermatome, i.e. numbness and 
tingling. Headache, fatigue and elevated body temper-
ature may also be present. These three manifestations, 
due to the lack of precise data, should be regarded 
as accompanying manifestations. In immunocom-
promised patients, the course of the disease may be 
untypical, the symptomatic period longer and the le-
sions irreversible and present within a higher number of 
dermatomes. Pain is the nearly inseparable and in most 
cases the most troublesome symptom of herpes zoster. 
Due to its varied nature, four qualitative categories of 
pain in herpes zoster may be distinguished:
www.advpm.eu 97
Małgorzata Malec-Milewska, Postherpetic neuralgia (PHN)
 — spontaneous constant pain independent of the 
stimulus;
 — spontaneous intermittent pain independent of 
the stimulus;
 — pain evoked by the stimulus, e.g. dynamic al-
lodynia;
 — increased sensitivity to pain in the form of par-
aesthesia (numbness, pruritus) or dysaesthesia 
(burning sensation).
Patients most commonly describe spontane-
ous pain in herpes zoster as burning, throbbing or 
sharp, shooting, stabbing pain. Spontaneous in-
termittent pain described as shooting, stabbing or 
electric-shock-like pain is characteristic of the pro-
dromal symptoms of herpes zoster. Pain described 
as burning pain is the most worrying type of pain, 
as it is characteristic of neuropathic pain. The burning 
nature of the pain is most likely a reflection of the im-
portant neurogenic pathomechanism of subsequent 
postherpetic neuralgia [1, 2]. Pain is usually severe. 
On the 11-point numeric rating scale (NRS), where 
0 refers to ‘no pain’ and 10 to ‘worst pain imagina-
ble’, pain in herpes zoster is usually rated at 4–10 
points. The severity of pain generally increases in the 
evening and at night. The vesicular skin lesions heal 
within 3–5 weeks. During this period a secondary 
bacterial infection may develop, which — if the first 
division of the trigeminal nerve is affected — leads to 
keratitis and iritis and may result in vision loss. The 
pain accompanies the skin lesions throughout their 
presence on the skin and should resolve upon healing 
of the rash. In rare cases, accompanying signs and 
symptoms are present, such as elevated body tem-
perature, enlarged lymph nodes, nuchal rigidity, 
headache and nausea [7–9].
The most popular classification of pain in her-
pes zoster is based on 3 phases:
 — acute pain — pain that is present for up to 30 
days after the onset of the rash;
 — subacute postherpetic neuralgia — pain of more 
than 30 days’ duration but resolves before the 
diagnosis of PHN is made;
 — postherpetic neuralgia — pain that persists be-
yond 120 days after the onset of the rash. The 
lack of a unified and unequivocal definition of 
PHN that would specify a universal timeframe 
makes it difficult to interpret many studies of 
postherpetic pain [14].
Management
In the acute stage of the disease, antiviral treat-
ment, prevention of secondary bacterial infection 
and pain relief are recommended. The combination 
treatment is particularly important in patients at 
a high risk of PHN (see below).
 — antiviral treatment: acyclovir 800 mg five 
times daily for 7 days (to be started immediately 
after the onset of the rash);
 — prevention of secondary bacterial infection;
 — Topical treatment: ointments, skin powder;
 — Pain relief: NSAIDs + paracetamol + tramadol. 
In severe pain: potent opioids;
 — nervous system blocks: infiltrative blocks, nerve 
trunk blocks, sympathetic nervous system blocks, 
central blocks. These interventions provide pain 
relief and may reduce the risk of PHN;
 — intravenous infusions of lidocaine — 3 mg/kg 
body weight over 30 minutes twice weekly until 
pain relief is achieved (prevention of the forma-
tion of pathological sodium channels — reduction 
of the risk of PHN);
 — antidepressants: amitriptyline 10–75 mg/day 
— reduction of the risk of PHN;
 — anticonvulsants: gabapentin/pregabalin —  re-
duction of the risk of PHN.
Postherpetic neuralgia (PHN)
Postherpetic neuralgia (PHN) refers to pain lo-
calised within dermatomes affected by the viral 
infection that persists (or recurs) after the infection 
and the healing of the skin lesions for more than 
3 months. The viral infection may cause injury to 
both sensory and motor nerve fibres with subsequent 
cicatrisation of a peripheral nerve trunk, spinal gan-
glion, nerve root and posterior horns of the spinal 
cord. Within the area of the healed skin lesions pain 
is described as burning, stinging, piercing, shooting 
or throbbing. The pain may be constant or intermit-
tent. A cold rainy weather and stress may increase 
the severity of the pain. The pain is also more severe 
in the evening and at night. The patient also devel-
ops sensation abnormalities in the form of allodynia 
(pain evoked by non-nociceptive stimuli, e.g. touch), 
hyperalgesia (exaggerated pain response to mechani-
cal and thermal stimuli, e.g. to contact of the affect-
ed skin with clothing) and hypoaesthesia (impaired 
touch and temperature sensation). In addition, sleep 
disorders and reduced activity are present in more 
than a half of the patients with PHN [7–9, 15]. Two 
non-mutually exclusive theories are currently most 
popular among researchers investigating PHN. The 
first theory suggests a role of decreased excitability 
of nerves within the ganglia and even within the 
spinal cord. The other theory suggests a chronic or 
smouldering viral infection within the nerve ganglia, 
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where infiltrates of cells characteristic of chronic in-
flammation have been documented [14]. The cause 
of PHN is unclear. Pain and abnormal sensation in 
the affected area are a result of inflammation, ex-
travasation, necrosis and degeneration that develop 
in the peripheral nerve, sympathetic ganglia, DRG, 
posterior roots of the spinal cord and ascending 
tracts of the spinal cord during the activation of the 
virus. The inflammation causes disintegration of the 
nervous system (peripheral sensitisation, impulse 
formation in pathological ectopic pacemakers of the 
nerve, central sensitisation, central reorganisation of 
A-beta fibres, functional impairment of the descend-
ing pain control pathways) [7–9, 16, 17].
Risk factors of PHN
The factors increasing the risk of PHN include: 
age, female sex, severe pain preceding the appear-
ance of the rash, involvement of the first division of 
the trigeminal nerve, involvement of non-neighbour-
ing dermatomes, diabetes, cancer or other immuno-
compromising conditions and a very severe course 
of the acute phase of the disease with severe pain 
and involvement of multiple dermatomes. However, 
PHN may also develop in patients with a very mild 
course of herpes zoster [7–10, 18]. The risk of PHN 
increases with age reaching 50%, 75% and nearly 
100% in patients over the age of 50, 65 and 80 
years, respectively. The pain may resolve spontane-
ously within several months but in some patients it 
persists for years or even a lifetime [7].
Can herpes zoster and postherpetic neuralgia 
be prevented?
Multicentre randomised double-blind studies of 
a total of 38.5 thousand patients over the age of 60 
years immunised with the antiviral vaccine Zostavax 
composed of live attenuated viruses demonstrated, 
over 3 years of follow-up, a statistically significant 
reduction in the incidence of herpes zoster follow-
ing immunisation of 61% [6, 19]. The incidence 
rate of herpes zoster was 11.1 per 1000 in the pla-
cebo group versus 5.4 per 1000 in the immunised 
group. Similarly, there was a statistically significant 
reduction in the incidence of PHN following immu-
nisation of 66.5% [9, 19]. Many studies have been 
conducted on the treatment of the active phase of 
herpes zoster with acyclovir. This antiviral drug, if 
used sufficiently early (within 48 hours of the onset 
of the skin lesions), is aimed to limit proliferation of 
the virus in DRG, cranial nerve ganglia and posterior 
horns of the spinal cord. Results of the analyses are, 
however, ambiguous and the confirmation of the 
role of early antiviral treatment in reducing the risk 
of PHN requires further, well-planned studies. Several 
studies in which various dosages of acyclovir were 
used negates the efficacy of antiviral therapy in the 
treatment of herpes zoster and the prevention of 
PHN. Other studies, however, confirm the efficacy 
of acyclovir at the dose of 800 mg five times daily. 
Studies confirming the efficacy of other antiviral 
agents, such as famciclovir and valaciclovir, have also 
been published. A study showing superiority of intra-
venous over oral acyclovir has also been published. 
Studies to assess acyclovir concentrations with oral 
and intravenous administration are, however, lacking 
[8, 9, 14]. The following measures are recommended 
in the prevention of PHN (particularly in high-risk 
patients): effective pain relief in the acute phase of 
the disease, sympathetic nervous system blocks, in-
travenous infusions of lidocaine and treatment with 
antidepressants and anticonvulsive agents [8, 9].
Management of PHN
The management of PHN depends on the dura-
tion and type of pain reported by the patient. If the 
patient is suffering from allodynia or hyperalgesia to 
stimuli the following are recommended:
 — topically, lidocaine patches 5%;
 — topically, 8% capsaicin;
 — topically, EMLA cream;
 — topically, acetylsalicylic acid;
 — topically, doxepin cream;
 — infiltrative blocks with 1% lidocaine;
 — sympathetic blocks;
 — epidural blocks [7–9].
Topical agents
EMLA cream 
EMLA cream is an oil-in-water emulsion con-
taining lidocaine and prilocaine in the ratio 1:1. 
This is a unique local anaesthetic formulation, 
as thanks to the high water content it is readily 
absorbed by the skin and thanks to the fact that 
the active substances are not present in the dis-
sociated form but in the form of more active basic 
compounds contained in fine droplets of fat sus-
pended in water it is possible to achieve effective 
skin anaesthesia at the depth of about 5 mm. EMLA 
cream is an eutectic mixture, which means that the 
melting point of the mixture differs from the melting 
points of its individual components. At the human 
skin temperature, the formulation maintains a liq-
uid form thanks to which it has a chance of being 
absorbed by the skin and of evoking its anaesthesia, 
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even over extensive areas of skin exceeding 400 cm2, 
with a single dose of 30–50 g (1 g of the cream con-
tains 25 mg of lidocaine and 25 mg of prilocaine). 
EMLA cream is indicated for skin anaesthesia to 
eliminate acute pain during procedures limited to 
the depth of the skin of about 5 mm (excision of 
small skin lesions, intravenous cannulation, painful 
punctures). EMLA cream is also indicated for the 
treatment of peripheral neuropathic pain, e.g. post-
herpetic neuralgia, especially in patients in whom 
blocks are contraindicated. When applying EMLA 
cream on a large area of the skin, the patient re-
quires haemodynamic monitoring and monitoring 
the levels of lidocaine and methaemoglobin, whose 
formation may be induced by prilocaine metabolites. 
The high price is a considerable factor that limits the 
use of EMLA cream in Poland and when the product 
needs to be applied on large areas of skin, another 
important limiting factor if the need for monitoring 
that requires hospitalisation of the patient [20, 21].
Lidocaine patches 5%
In contrast to EMLA cream, patches containing 
5% lidocaine exert their action mainly topically on 
pathological voltage-gated sodium channels (VGSCs) 
that are formed in the injured nerve. VGSCs ac-
cumulate at sites of injury and generate repetitive 
ectopic impulses. These channels are resistant to 
tetrodotoxin (TTR-R VGSCs) and are characterised 
by a high ability to bind lidocaine. Dissociation of 
lidocaine from TTR-R VGSCs is slow. After being 
released from the patch lidocaine penetrates the 
skin and only trace amounts (5%) enter the circula-
tion, which is why it does not cause cardiovascular 
complications but binds with the internal wall of 
pathological VGSCs which are formed in nerve end-
ings and keratinocytes.  
As a result of the blocking of pathological sodium 
channels ectopic impulses are suppressed, although 
this is not accompanied by the blocking of afferent 
nerve conduction (numbness does not develop). The 
other mechanism of action of lidocaine involves in-
hibition of the release of nociception mediators by 
keratinocytes, which account for 95% of the cells in 
the epidermis and are closely associated with nerve 
fibres. Keratinocytes are involved in the process of 
signalling and their activation induces sensitisa-
tion and depolarisation of primary sensory nerve 
endings through P2X receptors and increased ex-
pression of NK1 receptors in keratinocytes, which 
increases the release of substance P and leads to 
activation of the primary nociceptive sensory nerve 
endings [21, 22]. In addition, lidocaine patches ex-
ert a skin cooling effect and provide a mechanical 
protection of the affected skin.
In contrast to EMLA cream, lidocaine in the form 
of patches is only minimally absorbed to the cir-
culation (less than 5% enters the circulation) and 
the number needed to harm (NNH, the number of 
patients who need to be given a drug in order to 
cause clinically relevant adverse reactions in one of 
them) is very high (about 28). Topical lidocaine is rec-
ommended as the first-line treatment in localised 
peripheral neuropathic pain alone or in combination 
with another first-line drugs, which in the case of 
PHN may include antidepressants or gabapentinoids. 
The use of topical agents, such as lidocaine patches, 
may be preferred to systemic treatment, as the 
former are intended for local treatment of pain 
with minimum systemic absorption. Adverse reac-
tions, such as somnolence or vertigo, which often 
accompany systemic treatment, may be problematic, 
particularly in the elderly, in whom they increase 
the risk of falls. Lidocaine patches may also increase 
patient adherence to long-term treatment thanks to 
the ease of use: they are applied on the skin once 
daily or every 12 hours, which is in line with the ap-
proved label (up to 4 patches at a time), in contrast 
to creams or oral agents, which often have to be 
dosed several times over the 24-hour period. Dos-
ing every 12 hours provides a good analgesic effect 
throughout the entire 24 hours and the relatively 
long intervals between patch applications protect the 
skin from chafing. A metaanalysis performed in 2009 
that included 6 databases (32 studies, 38 publica-
tions) showed that 5% lidocaine was effective in the 
treatment of PHN (EBM level I evidence). The number 
needed to treat (NNT, the number of patients who 
need to be given a drug in order to obtain a positive 
treatment effect in one of them) is 2 and in the case 
of painful diabetic neuropathy its efficacy is compa-
rable to that of amitriptyline, capsaicin, gabapentin 
and pregabalin, although the use of 5% lidocaine 
is associated with fewer and less severe adverse re-
actions. The most common adverse reaction to lido-
caine patches 5% is local skin irritation. A drawback 
for Polish patients is the high price, which limits the 
widespread use of this formulation despite the fact 
that international guidelines recommend initiating 
treatment from lidocaine patches 5%, especially in 
patients with allodynia [21, 23–28].
Capsaicin
Capsaicin, or N-[(4-hydroxy-3-methoxyphenyl)
methyl]-8-methylnon-6-enamide, is a highly selective 
agonist of the transient receptor potential vanilloid-1 
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(TRPV1). The initial effect of capsaicin involves the 
activation of TPRV1 nociceptors in the skin, which 
leads to irritation and the development of erythema 
caused by the release of vasoactive neuropeptides, 
principally substance P. Following exposure to cap-
saicin skin nociceptors become less sensitive to 
various stimuli, hence the “late” action of capsaicin 
is often referred to as “anaesthesia” and is believed 
to be responsible for the resolution of pain. Sensa-
tions from skin nerves that do not express TPRV1 are 
unchanged, including touch and vibration sensation. 
Capsaicin-induced changes in skin nociceptors are 
reversible, as shown by studies in healthy volun-
teers which demonstrated normalisation of receptor 
function within several weeks. The mechanism of 
action of capsaicin, in addition to vanilloid receptor 
inactivation, also involves the removal of substance 
P from nerve endings.
Capsaicin applied topically in the form of a cream 
(0.025% or 0.075%) evoked a significant effect in 
diabetic neuropathy and NNT for this disease entity 
was 2.5–4.9. Capsaicin is also used in PHN (NNT 
5.3) and following nerve injury (NNT 3.5). NNH for 
capsaicin used for the treatment of neuropathic pain 
is 11.5 (range: 8.1–19.8) [28–32].
A randomised study of a patch containing 8% 
capsaicin in 299 patients with PHN versus a patch 
containing 0.04% capsaicin (control group) applied 
for 30, 60 or 90 minutes showed the greatest per-
centage of pain reduction in the group in whom 
a patch containing 8% capsaicin was applied for 
60 minutes with symptomatic relief being main-
tained from weeks 2 to 12 of follow-up. Controlled 
clinical studies also showed the efficacy of a patch 
containing 8% capsaicin with a single application 
onto painful areas of the skin (following a one-hour 
local anaesthesia of the skin with EMLA cream). In 
307 patients with neuropathy in the course of VZV 
infection, a pain reduction of 22.8% was already 
observed after a week and was maintained for 12 
weeks. Capsaicin patches were used alone and in 
combination with other drugs used in neuropathic 
pain. The use of patches containing 8% capsaicin 
in patients with diabetic neuropathy is poorly in-
vestigated and requires further studies. A patch 
containing 8% capsaicin is approved and available 
in Poland.
Capsaicin contained in the patch must be “deliv-
ered” to the skin and it is estimated that during the 
one-hour application, 1% of capsaicin is absorbed 
into the layers of the epidermis and dermis. Given 
the fact that the quantity of capsaicin released from 
the patch is proportional to the application area, the 
estimated possible total maximum dose for a surface 
area of 1000 cm2 is about 7 g. Assuming that a patch 
whose surface area is 1000 cm2 delivers about 1% of 
capsaicin for a patient weighing 60 kg, the maximum 
dose of capsaicin possible to use will be 0.12 mg/kg 
for 3 months (up to 4 patches per application). Each 
capsaicin patch measures 14 ´ 20 cm (280 cm2) and 
contains 179 mg of capsaicin (640 μg of capsaicin per 
cm2). The patch is applied on painful areas of the skin, 
which should be precisely marked and previously 
anaesthetised with a local anaesthetic, in line with 
the label. Many experts question the requirement 
to anaesthetise the skin before patch application. 
They argue that this requirement considerably pro-
tracts the procedure, it is difficult to properly dry the 
skin following application of the local anaesthetic, 
which may negatively affect the adhesiveness of the 
capsaicin patch, and despite the use of EMLA cream 
most patients still require an additional analgesic 
medication to relieve the acute pain accompanying 
patch application. At our facility, we always anaes-
thetise the skin with EMLA cream. We meticulously 
apply the cream on the skin area and then we apply 
the patch keeping a 1-cm safety margin. EMLA cream 
is applied for 60 minutes. The patch can only be ap-
plied on an intact and dry skin without signs of irrita-
tion (the skin must not be shaved, if hairs are present, 
they should be trimmed). The patch should be cut 
precisely to the area of the skin affected by pain. The 
patch is applied for 30–60 minutes. Throughout the 
procedure the patient’s blood pressure should be 
monitored (transient blood pressure surges may be 
observed, especially in hypertensive patients). If the 
pain persists or recurs, treatment may be repeated 
every 90 days. Statistically, the time to recurrence of 
pain and subsequent application of the patch rang-
es from 10–12 weeks to 8 months and increases with 
subsequent applications. If during or after patch ap-
plication the patient complains of severe pain, oral 
analgesics may be used (e.g. short-acting opioids: 
morphine, tramadol, tramadol plus paracetamol 
and/or rapid-onset NSAIDs: lornoxicam, nimesulide). 
The patch is removed by inward rolling. After remov-
ing the patch a thick layer of a cleansing gel should 
be applied for about 1 minute, the gel should then be 
removed and the skin washed with soap and water. 
The pain that appears directly after removal of the 
patch is best relieved by application of the cleansing 
gel and local cooling of the skin. No capsaicin dose 
adjustments are necessary in patients with renal or 
liver insufficiency. The drug is not recommended for 
patients below 18 years of age. The use of the drug 
on the skin of the head is not recommended due to 
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the risk of eye irritation. No clinical data are avail-
able on the use of capsaicin patches in pregnant or 
breastfeeding women. The most common adverse 
reactions have included transient burning sensation, 
pain, erythema and pruritus at the application site 
and have been mild to moderate. Apart from the 
warmth sensation at the site of patch application no 
other limitations of neurologic function have been 
observed. The efficacy of capsaicin should not only 
be assessed in terms of pain relief on the 11-point 
NRS but also in terms of changes in the nature of 
the pain, improvement of the quality of sleep and 
improvement of the quality of life. The high price 
is a disadvantage that limits the use of capsaicin 
patches in Poland [28–32].
Sympathetic nervous system blocks
The use of local anaesthetics in the treatment of 
early postherpetic pain was first reported in 1938 
and since that time they have become an element 
of management standards in this type of pain. The 
blocks are performed at intervals of one or two 
days in the total number of 3 to 10. The sooner 
this treatment is initiated, the higher the efficacy and 
the lower the number of blocks that yield satisfac-
tory outcomes. The efficacy of the blocks in the early 
period of 4 to 12 weeks is very high (85–98%) and 
during the period between 3 and 6 months is still 
good. The efficacy in the later period between 6 to 
12 months is low and beyond 12 months is minimal. 
According to Winnie, blocks should be used as a pre-
ventive measure before the onset of neuralgia in 
each patient over the age of 50 years (after [33]). 
Winnie supported his opinion on early initiation of 
sympathetic blocks with a very convincing explana-
tion of the pathophysiology of the changes which 
develop in herpes zoster. The VZV shows a high af-
finity for nerves and elicits inflammatory changes in 
them which are responsible for primary pain and 
the characteristic skin lesions. The inflammation 
causes a potent stimulation of the sympathetic 
nervous system leading to a very considerable re-
duction in blood supply to the nerve (up to 93%). 
The persistent ischaemia leads to changes in the 
endothelium of intraneural capillaries which leads to 
albumin leaks and oedema. The persistent oedema, 
by increasing intracapillary pressure, worsens the 
already present ischaemia and causes irreversible 
changes in the nerve. In addition, as a result of 
circulatory abnormalities, metabolic changes de-
velop, which mainly manifest by reduced glucose 
levels. All these changes lead to degeneration of 
A-delta fibres.
Animal studies demonstrated that the thin type 
C nerve fibres are much more resistant to metabolic 
changes and the existing ischaemia, thanks to which 
they retain their function for a longer time under path-
ological conditions. In the normal nerve, A-delta fi-
bres predominate over C fibres. In their theory of pain, 
the so-called gate control theory, Melzack and Wall 
[33, 34] pointed to the significance of impulses con-
ducted by both types of nerve fibres in the process of 
nociception. At the level f the posterior horn of the 
spinal cord impulses from A-delta fibres close the path 
to impulses conducted by the thin type C nerve fibres. 
Microscopic studies of the nerves affected by her-
pes zoster showed numerous type C fibres, while most 
of the thick A-delta fibres were destroyed and replaced 
by connective tissue. This phenomenon was described 
as the so-called fibre dissociation. Nerves altered in 
this way generate nociceptive stimuli without the pos-
sibility of being suppressed as they are transmitted 
to the CNS. Based on the results of neurophysiologic 
studies that prove the existence of the so-called an-
tinociception, Melzac also suggests that the primary 
neuronal dysfunction has its source not only in the 
spinal cord but also in higher-level structures, mainly 
in a part of the reticular formation of the brainstem. 
Under normal conditions, modulation or inhibition oc-
curs at all levels of the ascending nervous system. The 
partial lack of sensory fibres as a result of injury to the 
peripheral nerve leads to a decrease of general affer-
entation from the periphery and the resulting decrease 
of the inhibitory influence on the function of the 
nociception system. In conclusion, sympathetic pain 
syndromes may be characterised by an abnormal acti-
vity of the neurons in all parts of the nervous system. 
The role of individual parts of this system depends on 
a series of interconnected factors that include, among 
others, the degree and type of nervous system injury, 
individual psychological traits of the patient and, most 
importantly, duration of the chronic pain syndrome. 
The pathomechanism of pain in the early period 
is most likely localised in a more peripheral part of the 
nervous system. This is confirmed by clinical studies, 
as at this stage the efficacy of various methods that 
exclude the peripheral nervous system is the highest. 
It seems that one of the more important peripheral 
mechanisms present in all the forms of chronic pain 
syndromes is hypersensitivity of injured axons or ax-
onal endings to noradrenaline, which is released form 
sympathetic nervous system endings. Suppression of 
this mechanism by sympathetic blockade is considered 
the most effective treatment. Of particular significance 
is also the fact that this is also the least expensive 
treatment of postherpetic pain. It is therefore impor-
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tant for the clinician to know whether sympathetic 
blockade in a given period of the disease is likely to 
result in a relevant therapeutic benefit and to prevent 
the development of a persistent pain syndrome. The 
persistence of pain for weeks, months and years re-
sults in a gradual involvement of higher levels of the 
CNS. Due to the complicated pathomechanism of 
neuropathic pain and most of all due to the lack of 
detailed studies of the CNS, they are still a great un-
known despite the appearance of new hypotheses, 
which will, however, remain mere hypotheses until 
they have been proved [33–37].
Systemic treatment
Anticonvulsive drugs
Gabapentin acts by inhibiting the alpha2 subu-
nit of the G protein in the voltage-gated calcium 
channel. The starting dose is 100 mg daily. The full, 
therapeutically effective dose, which varies widely 
from 600 mg to 3600 mg daily, is achieved within 
about 30 days. NNT for gabapentin is 3.2 [7–9]. 
This wide range of doses results from the pharma-
cokinetic profile of gabapentin absorption, which 
is non-linear. This means that the higher the dose, 
the poorer the absorption, so that any deficiency of 
the drug is made up for by a high dose. 
Another anticonvulsive drug shown to be ef-
fective in the treatment of PHN in clinical stu-
dies is pregabalin, a derivative of gabapentin. The 
drug is used at doses from 150 mg to 600 mg daily 
in two or three divided doses. Both drugs differ in 
two respects: the onset of action and the pharma-
cokinetic profile of absorption, which affects the 
level of the therapeutic dose. Absorption of oral 
pregabalin is linear which means that the absorp-
tion of the drug does not depend on the dose. 
Thanks to this the maximum dose of pregabalin 
is six times lower than that of gabapentin. The full 
analgesic effect of pregabalin is observed within 
only 7 days, while in the case of gabapentin the full 
effect takes 4 weeks to develop. Both drugs cause 
similar adverse reactions: vertigo, imbalance, som-
nolence, peripheral oedema [38].
Intravenous lidocaine
Intravenous lidocaine at the dose of 3 mg/kg 
(NNT 2.3) blocks the pathological sodium channels.
Tricyclic antidepressants (TCAs)
Tricyclic antidepressants are useful in the treat-
ment of PHN and are characterised by the NNT of 
2.4 for the entire class. TCAs are effective in reliev-
ing spontaneous pain with burning sensation and 
paraesthesia. Amitriptyline is the most commonly 
used TCA. It is used at doses ranging from 25 mg 
to 75 mg daily. TCAs is a group of drugs that cause 
numerous adverse reactions. Caution is therefore 
recommended in the elderly, patients with seri-
ous cardiovascular co-morbidities, benign prostatic 
hyperplasia and glaucoma. Controlled studies show 
the efficacy of the selective serotonin and noradrena-
line reuptake inhibitors duloxetine and venlafaxine 
in the treatment of PHN. Duloxetine is given at 
doses from 60 mg to 120 mg daily and venlafaxine 
at doses from 75 mg to 150 mg daily.
Opioids
Tramadol is given at doses of up to 400 mg daily. 
Due to the fact that neuropathic pain is relatively 
resistant to opioids the initiation of potent opioids, 
such as fentanyl, morphine, buprenorphine or oxy-
codone, is recommended after performing tests of 
pharmacological analysis showing that this treat-
ment is effective [7–9].
Non-pharmacological treatments
Non-pharmacological treatments include:
 — TENS;
 — acupuncture;
 — laser therapy;
 — local cooling;
 — spinal cord stimulation [7–9].
Conclusions
The current standard in the treatment of PHN 
is combination treatment with an antidepressant, 
a topically-acting gabapentinoid (5% lidocaine and/or 
8% capsaicin) and an opioid. Of these drugs, gabap-
entin, pregabalin, TCA and lidocaine patches 5% are 
considered first-line treatments, and capsaicin and 
opioids are considered second-line treatments. As re-
gards opioids, the greatest number of studies have 
been conducted with tramadol and oxycodone. It 
is recommendable to start treatment with lidocaine 
patches and gradually add other classes of drugs, if 
necessary [5, 24, 25, 27, 31, 32, 39, 40].
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